Medi9: An all-time winner on the infection control battleground
Alcohol-free cleaning products independently proven to kill 99.9% of bacteria
Ebola. It’s a race against time.
Wherever you are, wherever you go, it’s making headlines. The deadly disease is wreaking havoc wherever it is found – and with the spread to the Western world, there’s no question about it: the problem is bad and it’s only getting worse.
Sure, it’s true that the outbreak is partially under control. The rate of infection is now exponential, though, and it’s clear that something more substantial and long-lasting is needed to tackle the problem. A concerted global effort with beds, helicopters and basic supplies is called for to prevent this threat to international peace and security becoming a reality. However, to step up the response further, a highly-effective sanitising product for infection prevention and control is mandatory.
This may seem obvious, but cleaning products currently used in the danger areas are not doing what they should. So this is where Medi9 offers a unique and necessary solution. Supplied by Nine Group International, Medi9 is a revolutionary range of alcohol-free products that has been independently proven to kill 99.9% of bacteria, spores, viruses and fungi on contact, including C.diff, MRSA, swine flu and Norovirus – with Ebola being the latest addition to the list. With these kill qualities, Medi9 products can not only be an invaluable help to those infected with this highly-infective and lethal virus, but also to those responding to it. Ebola is a social and humanitarian crisis – but it’s one that can be met head on if it’s addressed now and addressed in the right way.
Consisting of a full range of sanitisation products – ranging from hand gels and wipes to sprays, instrument cleaning tools and even air fogging systems – Medi9 has got it covered with its one-stop approach to infection control.
Although chlorine is definitely effective in dealing with the Ebola problem, the problems with transporting, storing and spraying the solution – particularly with the irritation it causes to skin – perhaps we should be asking ourselves now whether it is worth taking the risk of using a product that inflicts its own long-term side-effects on sufferers. Scientists have already admitted that the disease is ‘beyond the interventions we have in place’ and that it is ‘out of control’ with the resources in place – but Nine Group feels it can change this and the shocking statistics that have been described as ‘a vast underestimate of reality’ for the better.
